Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million | Tue, 09/02/2025 - 07:05
Summary
Zenas BioPharma and Royalty Pharma announced a funding agreement worth up to $300 million tied to obexelimab. Royalty Pharma will pay $75 million upfront, with additional payments linked to Phase 3 trial success and FDA approvals. Zenas plans to use the capital to advance obexelimab in IgG4-Related Disease and other autoimmune indications and to support a potential U.S. launch. The deal gives Zenas more runway through early 2027 and exchanges future sales royalties for development funding.
Funding
Amount
$300.0M
Total raised
Date
September 2, 2025
Announcement date
Investors
Royalty Pharma
Lead investors
Company
zenasbio.com
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected